JP2015518006A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518006A5
JP2015518006A5 JP2015514242A JP2015514242A JP2015518006A5 JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5 JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5
Authority
JP
Japan
Prior art keywords
human
allergic condition
composition
hydrochloride
performed via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518006A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042925 external-priority patent/WO2013177594A2/en
Publication of JP2015518006A publication Critical patent/JP2015518006A/ja
Publication of JP2015518006A5 publication Critical patent/JP2015518006A5/ja
Pending legal-status Critical Current

Links

JP2015514242A 2012-05-25 2013-05-28 キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 Pending JP2015518006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651741P 2012-05-25 2012-05-25
US61/651,741 2012-05-25
PCT/US2013/042925 WO2013177594A2 (en) 2012-05-25 2013-05-28 Xylitol-based anti-mucosal compositions and related methods and compositions

Publications (2)

Publication Number Publication Date
JP2015518006A JP2015518006A (ja) 2015-06-25
JP2015518006A5 true JP2015518006A5 (enExample) 2017-03-23

Family

ID=49621806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514242A Pending JP2015518006A (ja) 2012-05-25 2013-05-28 キシリトール系の抗粘膜組成物及び関連する方法並びに組成物

Country Status (13)

Country Link
US (3) US8709508B2 (enExample)
EP (1) EP2854781A4 (enExample)
JP (1) JP2015518006A (enExample)
KR (1) KR20150011807A (enExample)
CN (1) CN104334164A (enExample)
AU (1) AU2013266067B2 (enExample)
BR (1) BR112014029442A2 (enExample)
CA (1) CA2870158C (enExample)
IL (1) IL235875A (enExample)
MX (1) MX2014013998A (enExample)
RU (1) RU2607892C2 (enExample)
WO (1) WO2013177594A2 (enExample)
ZA (1) ZA201408594B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
BR112014029442A2 (pt) 2012-05-25 2017-06-27 Xlear Inc composições antimucosas à base de xilitol e métodos e composições relacionados
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US20180008598A1 (en) * 2016-07-07 2018-01-11 Xlear, Inc. Antibacterial nasal compositions and related methods
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
CN113727736A (zh) 2018-12-10 2021-11-30 通用医疗公司 色甘酸酯及其用途
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2021216869A1 (en) 2020-04-24 2021-10-28 Joseph Scivoletto Nasal spray composition
WO2022140795A2 (en) * 2020-12-23 2022-06-30 Spotlight Therapeutics Nucleic acid binding protein formulations and uses thereof
CN116211884B (zh) * 2023-02-16 2024-05-17 海孵(海南自贸区)医疗科技有限责任公司 一种鼻腔喷雾剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01172324A (ja) * 1987-12-15 1989-07-07 Armour Internatl Co コレスチラミン組成物及びその製造法
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
JP2001524108A (ja) * 1997-04-30 2001-11-27 ワーナー−ランバート・カンパニー 局所経鼻抗炎症組成物
US6054143A (en) 1998-03-24 2000-04-25 Jones; Alonzo H. Xylitol delivery
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
EP1660056A4 (en) * 2003-08-15 2008-12-17 Arius Two Inc ADHESIVE BIOERODIBLE TRANSMUCOSAL DRUG DELIVERY SYSTEM
US20060034947A1 (en) 2004-06-02 2006-02-16 Burr James B Erythritol compositions for nasopharynx cleansing
MX344036B (es) * 2004-11-24 2016-12-02 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y metodos de uso de la misma.
GB0426068D0 (en) * 2004-11-29 2004-12-29 Passion For Life Healthcare Lt Composition with bacteria blocking action
US20060120967A1 (en) * 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
WO2008070264A2 (en) * 2006-10-10 2008-06-12 Case Western Reserve University Nasal spray composition and method for treating rhinitis, sinusitis or both
WO2010078419A2 (en) * 2008-12-31 2010-07-08 Bzmi, Llc Herbal-based nasal solution and method of use thereof
DE202010012255U1 (de) * 2010-09-07 2010-11-18 Krewel Meuselbach Gmbh Nasenspray
BR112014029442A2 (pt) 2012-05-25 2017-06-27 Xlear Inc composições antimucosas à base de xilitol e métodos e composições relacionados

Similar Documents

Publication Publication Date Title
JP2015518006A5 (enExample)
CA2870158C (en) Xylitol-based anti-mucosal compositions and related methods and compositions
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
HRP20171739T1 (hr) Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
CO6400184A2 (es) Formulaciones galénicas de compuestos orgánicos
HRP20151381T1 (hr) Nazalni sprej
WO2010024956A3 (en) Antihistamine and antihistamine-like nasal application, products, and method
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
JP2013534527A5 (enExample)
JP2016525548A5 (enExample)
ATE507818T1 (de) Orale verabreichung eines calcitonins
HRP20192010T1 (hr) Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
JP2016502991A5 (enExample)
BR112013019876A2 (pt) formulação farmacêutica, uso da formulação farmacêutica, frasco e kit
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
BR112015030341A2 (pt) formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
JP2014530847A5 (enExample)
WO2014011949A3 (en) Neuroprotective cb2 receptor agonists
AR084195A1 (es) Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma
BR112016011999A2 (pt) Derivados de amida para agonista de gpr119